Cantor Fitzgerald Predicts TSHA FY2025 Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Taysha Gene Therapies in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($0.40) for the year. Cantor Fitzgerald has a “Overweight” rating and a $7.00 price objective on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share.

Several other analysts have also issued reports on the stock. Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Canaccord Genuity Group lifted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Finally, Needham & Company LLC restated a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Monday, January 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Price Performance

TSHA opened at $1.53 on Wednesday. The business has a 50 day moving average of $2.12 and a 200-day moving average of $2.10. The stock has a market capitalization of $313.56 million, a price-to-earnings ratio of 2.43 and a beta of 0.95. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 1-year low of $1.19 and a 1-year high of $4.32.

Hedge Funds Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in shares of Taysha Gene Therapies by 1.3% in the third quarter. JPMorgan Chase & Co. now owns 3,001,397 shares of the company’s stock valued at $6,033,000 after acquiring an additional 37,844 shares during the last quarter. Franklin Resources Inc. acquired a new position in Taysha Gene Therapies during the 3rd quarter worth about $201,000. Barclays PLC grew its holdings in Taysha Gene Therapies by 356.0% during the 3rd quarter. Barclays PLC now owns 247,280 shares of the company’s stock worth $513,000 after acquiring an additional 193,046 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Taysha Gene Therapies by 23.7% in the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after acquiring an additional 682,273 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Taysha Gene Therapies during the third quarter worth approximately $931,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.